Cogent Biosciences, Inc. Operating Income Loss

• Cogent Biosciences, Inc. showed a decrease of -20.8% in Operating Income Loss from 2024 to 2025.
• This data is from Cogent Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), Cogent Biosciences, Inc.'s Operating Income Loss has declined by 1,174.7%.
• Historical annual values: Fiscal year 2025: -$333.36 million | Fiscal year 2024: -$275.94 million | Fiscal year 2023: -$208.13 million | Fiscal year 2022: -$147.84 million | Fiscal year 2021: -$75.55 million | Fiscal year 2020: -$82.20 million | Fiscal year 2019: -$32.18 million | Fiscal year 2018: -$36.01 million | Fiscal year 2017: -$26.15 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026